We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.1B
1-Year Est. Return
57.92%
This Fund
S&P 500
This Quarter
Est. Return
+12.48%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.63B
AUM Growth
-$655M
(-15%)
Cap. Flow
-$792M
Cap. Flow
% of AUM
-21.84%
Top 10 Holdings %
Top 10 Hldgs %
31.08%
Holding
113
New
24
Increased
24
Reduced
34
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$90.1M |
| 2 |
AerCap
AER
|
+$80M |
| 3 |
Pfizer
PFE
|
+$73.2M |
| 4 |
Illumina
ILMN
|
+$56.4M |
| 5 |
Equifax
EFX
|
+$54M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$262M |
| 2 |
Vulcan Materials
VMC
|
+$208M |
| 3 |
Bausch Health
BHC
|
+$108M |
| 4 |
AGN
Allergan Inc
AGN
|
+$107M |
| 5 |
AGN
Allergan plc
AGN
|
+$82.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.17% |
| 2 | Industrials | 10.32% |
| 3 | Materials | 6.21% |
| 4 | Technology | 5.36% |
| 5 | Financials | 3.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PDCO
51
DELISTED
Patterson Companies, Inc.
PDCO
| $25.9M | 0.71% |
531,218
+263,828
| +99% | +$13.1M |
|
|
BLUE
52
DELISTED
bluebird bio
BLUE
| $24.1M | 0.67% |
15,420
-13,549
| -47% | -$17.9M |
|
53
Aramark
ARMK
$15.1B
| $23.9M | 0.66% |
+1,045,039
| New | +$23.9M |
|
|
THOR
54
DELISTED
THORATEC CORPORATION
THOR
| $23.7M | 0.65% |
565,799
+98,888
| +21% | +$3.77M |
|
55
Delta Air Lines
DAL
$58.3B
| $22.6M | 0.62% |
+502,043
| New | +$23.3M |
|
|
OREX
56
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $22.5M | 0.62% |
287,049
-30,927
| -10% | -$1.92M |
|
57
Molina Healthcare
MOH
$10.2B
| $20.5M | 0.57% |
304,534
-398,979
| -57% | -$23.1M |
|
|
ANAC
58
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $20M | 0.55% |
346,314
-99,805
| -22% | -$4.24M |
|
|
OCR
59
DELISTED
OMNICARE INC
OCR
| $19M | 0.52% |
247,079
-11,992
| -5% | -$911K |
|
|
ALDR
60
DELISTED
Alder Biopharmaceuticals
ALDR
| $18.2M | 0.5% |
630,466
+300,518
| +91% | +$8.25M |
|
61
Halliburton
HAL
$26.4B
| $15.5M | 0.43% |
+353,229
| New | +$14.7M |
|
|
ACOR
62
DELISTED
Acorda Therapeutics
ACOR
| $15.5M | 0.43% |
3,877
-3,396
| -47% | -$15.6M |
|
63
Carnival Corporation Ltd
CCL
$38B
| $15.4M | 0.42% |
+321,865
| New | +$14.5M |
|
64
Netflix
NFLX
$305B
| $14.7M | 0.41% |
+2,472,120
| New | +$15M |
|
65
QuidelOrtho
QDEL
$1.13B
| $12.9M | 0.35% |
476,800
+244,453
| +105% | +$6.24M |
|
|
WCG
66
DELISTED
Wellcare Health Plans, Inc.
WCG
| $12.8M | 0.35% |
139,680
-352,834
| -72% | -$29.5M |
|
|
ATHN
67
DELISTED
Athenahealth, Inc.
ATHN
| $12.7M | 0.35% |
+106,714
| New | +$14.2M |
|
68
Agilent Technologies
A
$39.2B
| $12.4M | 0.34% |
298,200
-1,381,314
| -82% | -$55.9M |
|
69
Bruker
BRKR
$9.79B
| $11.9M | 0.33% |
642,313
-188,506
| -23% | -$3.57M |
|
|
KITE
70
DELISTED
Kite Pharma, Inc.
KITE
| $10.2M | 0.28% |
175,994
-40,658
| -19% | -$2.72M |
|
|
HDP
71
DELISTED
Hortonworks, Inc.
HDP
| $8.8M | 0.24% |
368,981
+336,484
| +1,035% | +$7.81M |
|
|
ARAV
72
DELISTED
Aravive, Inc. Common Stock
ARAV
| $8.76M | 0.24% |
79,514
-65,397
| -45% | -$7.67M |
|
73
Acadia Pharmaceuticals
ACAD
$4.55B
| $8.14M | 0.22% |
249,855
-43,710
| -15% | -$1.5M |
|
74
Integra LifeSciences
IART
$1.33B
| $7.44M | 0.21% |
+295,257
| New | +$6.98M |
|
|
AERI
75
DELISTED
Aerie Pharmaceuticals
AERI
| $7.38M | 0.2% |
+235,445
| New | +$6.82M |
|
Similar funds
DAM
MAM
LCM
DAM
KCM
CF
MIA
AC
PFM Health Sciences's Q1 2015 Portfolio in Review
As of Q1 2015, PFM Health Sciences held 113 positions worth $3.63B, down 15% from $4.28B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
PFM Health Sciences withdrew a net $792M in Q1 2015, closing 30 positions and reducing 34 holdings. Its most notable exit was Microsoft, an estimated $262M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 50% a quarter earlier, followed by Industrials and Materials.
Against the trend, PFM Health Sciences opened a new position in Jazz Pharmaceuticals worth $90.7M.
- PFM Health Sciences's largest Q1 2015 buy was Jazz Pharmaceuticals: 525,003 shares worth $90.7M.
- PFM Health Sciences added most to AerCap in Q1 2015, an estimated $80M increase.
- PFM Health Sciences's biggest Q1 2015 reduction was Vulcan Materials, cutting an estimated $208M.
- PFM Health Sciences fully exited Microsoft in Q1 2015, selling an estimated $262M.
- PFM Health Sciences's ten largest holdings make up 31% of its $3.63B portfolio in Q1 2015.
- PFM Health Sciences opened 24 new positions and closed 30 in Q1 2015.
- PFM Health Sciences's portfolio value fell 15% quarter-over-quarter to $3.63B.
Based on PFM Health Sciences's 13F filing for Q1 2015, filed 15 May 2015.